Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Shares Issued: 2023-2025

Historic Shares Issued for NewAmsterdam Pharma Co N.V (NAMS) over the last 3 years, with Sep 2025 value amounting to $5.6 million.

  • NewAmsterdam Pharma Co N.V's Shares Issued was N/A to $5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.3 million, marking a year-over-year change of. This contributed to the annual value of $13.8 million for FY2024, which is 59.60% up from last year.
  • Per NewAmsterdam Pharma Co N.V's latest filing, its Shares Issued stood at $5.6 million for Q3 2025, which was up 64.08% from $3.4 million recorded in Q2 2025.
  • NewAmsterdam Pharma Co N.V's Shares Issued's 5-year high stood at $8.8 million during Q1 2024, with a 5-year trough of $1,000 in Q3 2023.
  • In the last 3 years, NewAmsterdam Pharma Co N.V's Shares Issued had a median value of $4.7 million in 2024 and averaged $4.4 million.
  • In the last 5 years, NewAmsterdam Pharma Co N.V's Shares Issued spiked by 266.35% in 2024 and then dropped by 26.49% in 2025.
  • Quarterly analysis of 3 years shows NewAmsterdam Pharma Co N.V's Shares Issued stood at $1,000 in 2023, then decreased by 25.22% to $340,000 in 2024, then decreased by 26.49% to $5.6 million in 2025.
  • Its last three reported values are $5.6 million in Q3 2025, $3.4 million for Q2 2025, and $7.9 million during Q1 2025.